Telithromycin use and spontaneous reports of hepatotoxicity.
OBJECTIVE
Recent reports have described cases of telithromycin-related hepatotoxicity. The objective of this study is to quantify the effect of telithromycin use on the risk of hepatotoxicity.


METHODS
We conducted a spontaneous-report case-control study of hepatotoxicity in telithromycin recipients using reports from the US FDA Adverse Event Reporting System. Reports from between 1 January 2005 and 30 June 2005 were examined. Cases included reports of patients with abnormal liver function tests, hepatocellular damage and hepatic impairment, while patients with reported conditions with similar reporting probabilities were considered as controls. The primary outcome measure of the analysis was the reporting odds ratio (ROR) evaluating the a priori hypothesis that telithromycin use confers an elevated risk of hepatotoxicity relative to other agents.


RESULTS
A total of 2219 cases and 20,667 controls were identified. We estimated an ROR for hepatotoxicity associated with telithromycin compared with other agents of 1.82 (95% CI 1.12, 2.96) after controlling for age and gender, approximating an 82% excess risk in users of telithromycin relative to users of other agents.


CONCLUSIONS
This analysis is the first to specifically quantify the effect of telithromycin on the risk of hepatotoxicity. Telithromycin use may increase the risk of hepatotoxicity by >80%. Biases inherent in spontaneous reports include under-reporting of events and differential or time-varying reporting due to enhanced clinician awareness. Future studies should employ alternative data sources because of the inherent limitations of passive surveillance systems.
Dore
David D
DD
Department of Community Health, Brown Medical School, Providence, RI 02903, USA. david_dore@brown.edu
DiBello
Julia R
JR
Lapane
Kate L
KL
D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D006801:Humans; D048628:Ketolides / Q000009:adverse effects*; D008107:Liver Diseases / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D014481:United States / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin
Otolaryngol Head Neck Surg. 2004 Sep;131(3):207-14
15365537
Am J Rhinol. 2003 Nov-Dec;17 (6):369-77
14750614
Arch Intern Med. 2004 Jun 14;164(11):1243-6
15197053
Am J Public Health. 2005 Mar;95(3):458-65
15727977
J Antimicrob Chemother. 1994 Mar;33(3):387-401
8040106
JAMA. 2000 Dec 20;284(23):3036-9
11122591
J Allergy Clin Immunol. 2005 Feb;115(2):S1-13
15696068
N Engl J Med. 2006 Apr 13;354(15):1589-600
16611950
South Med J. 2005 Sep;98 (9):863-8
16217977
JAMA. 2001 Aug 15;286(7):831-3
11497537
Drug Saf. 1999 Feb;20(2):109-17
10082069
Ann Intern Med. 2006 Mar 21;144(6):415-20
16481451
Drug Alcohol Depend. 2004 Jun 11;74(3):223-34
15194200
Addiction. 2003 Sep;98(9):1209-28
12930209
Ann Intern Med. 2002 Dec 17;137(12):947-54
12484709
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519-23
15317031
Infection. 2002 Dec;30(6):378-86
12478329
J Antimicrob Chemother. 2004 Aug;54(2):515-23
15269191
Ear Nose Throat J. 2003 Aug;82(8):576-80, 82-4, 586 passim
14503094
Chest. 2005 Oct;128(4):1980-8
16236845
Clin Ther. 2004 Jan;26(1):48-62
14996517
Pharmacoepidemiol Drug Saf. 2005 Dec;14(12):869-75
15818636
Clin Ther. 1998;20 Suppl C:C40-4
9915089
Clin Gastroenterol Hepatol. 2005 Dec;3(12):1260-8
16361053